CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 4.3% – What’s Next?

Shares of CytoMed Therapeutics Limited (NASDAQ:GDTCGet Free Report) dropped 4.3% during trading on Monday . The stock traded as low as $2.55 and last traded at $2.69. Approximately 17,866 shares changed hands during trading, a decline of 96% from the average daily volume of 462,595 shares. The stock had previously closed at $2.81.

CytoMed Therapeutics Price Performance

The business has a 50 day moving average price of $2.69 and a two-hundred day moving average price of $2.19.

CytoMed Therapeutics Company Profile

(Get Free Report)

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Featured Articles

Receive News & Ratings for CytoMed Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoMed Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.